复发性卵巢癌-话题@MedSci

#复发性卵巢癌#

43篇内容 | 2167人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1349620, encodeId=d34613496200f, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, objectType=article, longId=194712, objectId=cf45194e12da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf45194e12da, replyNumber=0, likeNumber=77, createdTime=2020-05-27, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf45194e12da, moduleTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf45194e12da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349619, encodeId=b80913496190f, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测, objectType=article, longId=194408, objectId=c521194408e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c521194408e5, replyNumber=0, likeNumber=81, createdTime=2020-05-21, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c521194408e5, moduleTitle=尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c521194408e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349618, encodeId=1a2d1349618a2, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, objectType=article, longId=192935, objectId=dc37192935a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc37192935a7, replyNumber=0, likeNumber=66, createdTime=2020-04-26, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc37192935a7, moduleTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc37192935a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349617, encodeId=a234134961eac, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=62, createdTime=2020-03-16, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349616, encodeId=697e1349616e3, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, objectType=article, longId=186740, objectId=76ac186e40ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ac186e40ac, replyNumber=0, likeNumber=78, createdTime=2020-01-27, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ac186e40ac, moduleTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ac186e40ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349615, encodeId=baea1349615d0, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, objectType=article, longId=185399, objectId=b7f018539947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7f018539947, replyNumber=0, likeNumber=61, createdTime=2019-12-30, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7f018539947, moduleTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7f018539947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349614, encodeId=af45134961492, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, objectType=article, longId=183027, objectId=fd5a18302e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5a18302e46, replyNumber=0, likeNumber=110, createdTime=2019-11-16, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5a18302e46, moduleTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5a18302e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349613, encodeId=028d1349613b6, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, objectType=article, longId=181868, objectId=ccf018186817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccf018186817, replyNumber=0, likeNumber=83, createdTime=2019-10-25, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccf018186817, moduleTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccf018186817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349612, encodeId=a8071349612c4, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=肿瘤电场疗法治疗复发性卵巢癌的III期关键性试验现已开展, objectType=article, longId=162856, objectId=38df16285682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38df16285682, replyNumber=0, likeNumber=89, createdTime=2019-03-26, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38df16285682, moduleTitle=肿瘤电场疗法治疗复发性卵巢癌的III期关键性试验现已开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38df16285682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349611, encodeId=5cfb134961137, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Clovis Oncology宣布欧洲委员会批准Rubraca用于复发性卵巢癌的维持治疗, objectType=article, longId=158910, objectId=54ad1589109b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ad1589109b, replyNumber=0, likeNumber=61, createdTime=2019-01-27, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ad1589109b, moduleTitle=Clovis Oncology宣布欧洲委员会批准Rubraca用于复发性卵巢癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54ad1589109b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349610, encodeId=fae7134961057, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=PARP抑制剂治疗复发性卵巢癌专家共识, objectType=article, longId=151855, objectId=647a151855af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=647a151855af, replyNumber=0, likeNumber=76, createdTime=2018-10-26, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=647a151855af, moduleTitle=PARP抑制剂治疗复发性卵巢癌专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=647a151855af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349609, encodeId=62b11349609fe, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗, objectType=article, longId=134828, objectId=ba40134828dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba40134828dd, replyNumber=0, likeNumber=97, createdTime=2018-04-12, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba40134828dd, moduleTitle=Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba40134828dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349608, encodeId=e40713496086a, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=肿瘤治疗电场为复发性卵巢癌患者带来新希望，无进展生存期延长两倍！, objectType=article, longId=117443, objectId=670111e4433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=670111e4433a, replyNumber=0, likeNumber=75, createdTime=2017-10-26, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=670111e4433a, moduleTitle=肿瘤治疗电场为复发性卵巢癌患者带来新希望，无进展生存期延长两倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=670111e4433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349607, encodeId=f8ee134960e36, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Lancet：Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。, objectType=article, longId=112754, objectId=8d18112e5477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d18112e5477, replyNumber=0, likeNumber=75, createdTime=2017-09-15, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d18112e5477, moduleTitle=Lancet：Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d18112e5477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349606, encodeId=b3c21349606b8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, objectType=article, longId=106877, objectId=eba21068e7a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba21068e7a6, replyNumber=0, likeNumber=62, createdTime=2017-07-28, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba21068e7a6, moduleTitle=Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba21068e7a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, objectType=article, longId=103156, objectId=d8d010315642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d010315642, replyNumber=0, likeNumber=70, createdTime=2017-06-25, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d010315642, moduleTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d010315642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349604, encodeId=8741134960454, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Lancet Oncol：贝伐单抗可提高铂化疗敏感的复发性卵巢癌患者生存率, objectType=article, longId=96885, objectId=7d279688506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d279688506, replyNumber=0, likeNumber=0, createdTime=2017-04-26, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d279688506, moduleTitle=Lancet Oncol：贝伐单抗可提高铂化疗敏感的复发性卵巢癌患者生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d279688506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349603, encodeId=714e134960357, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, objectType=article, longId=79625, objectId=03fde96257d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fde96257d, replyNumber=0, likeNumber=46, createdTime=2016-10-11, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fde96257d, moduleTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fde96257d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349602, encodeId=18a41349602ac, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=NEJM：Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期, objectType=article, longId=79605, objectId=925ae9605d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925ae9605d0, replyNumber=0, likeNumber=77, createdTime=2016-10-10, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925ae9605d0, moduleTitle=NEJM：Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925ae9605d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349601, encodeId=8f7f134960170, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, objectTitle=Clin Cancer Res：联合疗法有效治疗复发性卵巢癌, objectType=article, longId=42710, objectId=180b42e10a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=180b42e10a6, replyNumber=0, likeNumber=61, createdTime=2014-11-20, rootId=0, userName=windight, userId=ec9955, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=180b42e10a6, moduleTitle=Clin Cancer Res：联合疗法有效治疗复发性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=180b42e10a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性卵巢癌

2020-05-29

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）

2020-05-27

docwu2019 (审核中...)

前往app查看评论内容

#复发性卵巢癌#

尹如铁教授：HRD检测扩大复发性卵巢癌后线治疗获益人群，国内产品首次用于PARPi临床试验入组HRD检测

2020-05-21

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效

2020-04-26

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-03-16

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率

2020-01-27

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗

2019-12-30

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期

2019-11-16

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗

2019-10-25

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

肿瘤电场疗法治疗复发性卵巢癌的III期关键性试验现已开展

2019-03-26

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Clovis Oncology宣布欧洲委员会批准Rubraca用于复发性卵巢癌的维持治疗

2019-01-27

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

PARP抑制剂治疗复发性卵巢癌专家共识

2018-10-26

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗

2018-04-12

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

肿瘤治疗电场为复发性卵巢癌患者带来新希望，无进展生存期延长两倍！

2017-10-26

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Lancet：Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。

2017-09-15

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗

2017-07-28

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

2017-06-25

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Lancet Oncol：贝伐单抗可提高铂化疗敏感的复发性卵巢癌患者生存率

2017-04-26

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS

2016-10-11

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

NEJM：Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期

2016-10-10

windight (审核中...)

前往app查看评论内容

#复发性卵巢癌#

Clin Cancer Res：联合疗法有效治疗复发性卵巢癌

2014-11-20

科室
- - 订阅+
  - 更多科室
工具
服务